PathAI
AI-powered pathology platform for accurate diagnostic insights.
PathAI delivers robust AI-assisted slide analysis with automated tumor grading and biomarker quantification, backed by deep learning models trained on large datasets. Its strengths lie in clinical and biopharma applications, improving diagnostic accuracy and turnaround times. However, enterprise-only pricing and the prerequisite of digitized slides limit accessibility for smaller labs. Buyers should request a demo to assess fit, and consider alternatives like Paige AI or Ibex for more flexible deployment options.
Verified 18d ago · liveness 75/100 · cite: rightaichoice.com/tools/pathai
- Pathology labs seeking AI-assisted diagnostic accuracy
- Researchers requiring quantitative biomarker analysis
- Hospitals aiming to reduce turnaround times for pathology reports
- Large biopharma companies with clinical trial pathology needs
- Organizations without a digital pathology infrastructure
- Teams needing lightweight, low-cost AI tools
- Users requiring self-service deployment without vendor support
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip PathAI if your lab lacks digital pathology infrastructure or you need a low-cost, self-service AI tool with transparent pricing.
Digitized slide scanning equipment is required, which can add thousands of dollars in upfront costs.
PathAI uses custom enterprise pricing, generally suited for large labs and biopharma firms with dedicated budgets. Smaller labs may find Paige AI or Ibex more affordable with published tiers.
In short
PathAI — AI-powered pathology platform for accurate diagnostic insights. Best for Pathology labs seeking AI-assisted diagnostic accuracy, Researchers requiring quantitative biomarker analysis, Hospitals aiming to reduce turnaround times for pathology reports. Contact Sales pricing.
Viability Score
How likely is PathAI to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- AI-assisted slide analysis
- Automated tumor grading
- Biomarker quantification
- Diagnostic decision support
- Workflow integration tools
- Collaboration features
- Data management and analytics
- Quality assurance tools
- Clinical trial pathology support
- Companion diagnostics development
- Endpoint analysis for research
About PathAI
PathAI is an AI-powered pathology platform designed to assist pathologists and researchers in making more accurate and efficient diagnoses. Using deep learning algorithms, PathAI analyzes digitized tissue samples to identify biomarkers, grade tumors, and provide quantitative insights. The platform integrates into clinical and biopharma workflows, offering AI-assisted diagnosis, biomarker quantification, quality assurance, and data management tools. It aims to reduce turnaround times and improve diagnostic consistency, making it suitable for large labs and research organizations with digital pathology infrastructure.
Behind the Verdict
PathAI stands out in the pathology AI space with its focus on clinical-grade accuracy and quantitative biomarker analysis. The platform's deep learning models are designed to augment pathologists, not replace them, and features like automated tumor grading and quality assurance tools can help standardize diagnoses across labs. For biopharma companies, the platform supports clinical trial pathology, companion diagnostics, and endpoint analysis, which can accelerate drug development. However, the vendor-dependent deployment model and lack of publicly available pricing may deter smaller labs. The platform requires digitized slides, so labs without digital pathology infrastructure must factor in scanner costs. Compared to Paige AI, which offers broader CE-marked products, or Ibex, which provides AI decision support with cloud deployment, PathAI's custom pricing model leans toward enterprise-scale organizations. Strengths: deep learning accuracy, biopharma integration, quality assurance. Weaknesses: no transparent pricing, limited integrations data, no free trial.
Researching PathAI? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas PathAI actually fits — and what changes day-one when you adopt it.
Reviewing 50 daily cancer biopsies with AI-assisted slide analysis and automated tumor grading.
Outcome: Reduced diagnostic time by 30% and improved inter-pathologist consistency.
Analyzing tissue samples from a phase 3 trial to quantify PD-L1 biomarker expression.
Outcome: Faster endpoint analysis with standardized quantitative scoring.
Deploying PathAI after integrating digital scanners to reduce turnaround times.
Outcome: Achieved average 2-day reduction in diagnosis turnaround for prioritized cases.
Use Cases
- Pathologists reviewing cancer biopsies with AI assistance to reduce diagnostic time
- Biopharma companies analyzing tissue samples for clinical trial endpoints
- Labs quantifying biomarkers for personalized treatment decisions
- Hospitals aiming to reduce turnaround times for pathology reports
- Research institutions conducting high-volume biomarker studies
Limitations
Enterprise pricing may be prohibitive for small labs; requires digitized slides for full benefit; not available for direct purchase online; limited integration information publicly available; vendor-dependent deployment and support.
as of 2026-06-30
12-month cost
Project the real annual outlay, including the implied monthly cost when only an annual tier is published.
Vendor list price only. Add-on usage, seat overages, and contract minimums are surfaced under Hidden costs & gotchas.
Plans compared
For each published PathAI tier: who it actually fits, and what it adds vs. the previous tier. Cross-reference the cost calculator above for projected annual outlay.
Clinical
Custom
Ideal for
Hospital pathology labs and diagnostic centers requiring AI-assisted sign-out and quality assurance.
What this tier adds
Starting tier focused on clinical diagnostics, includes AI-assisted diagnosis and quality assurance tools.
Biopharma
Custom
Ideal for
Pharmaceutical and biotech companies using pathology for clinical trials and companion diagnostics.
What this tier adds
Adds clinical trial support and endpoint analysis compared to the Clinical tier.
Where the pricing makes sense
The company stage and team size where PathAI's pricing actually pencils out — and where peers do it cheaper.
PathAI uses custom enterprise pricing, generally suited for large labs and biopharma firms with dedicated budgets. Smaller labs may find Paige AI or Ibex more affordable with published tiers.
Setup time & first value
How long it actually takes to get something useful out of PathAI — broken out by persona, not the marketing-page minute.
Setup involves digitizing slides and integrating with existing LIS/AP systems; typical deployment takes 2-4 weeks with vendor support for clinical labs. Biopharma projects may require additional validation time.
Switching to or from PathAI
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual glass-slide workflow: Requires digital scanner integration, then PathAI validation on retrospective cases (4-8 weeks).
- ↗To Paige AI: Export annotated slide data and retrain models on Paige platform.
- ↗To Ibex: Convert slide archives and diagnostic data to Ibex format with vendor assistance.
Resources & Guides
Official links
Tools that pair well with PathAI
Common stack mates teams adopt alongside PathAI, with the specific reason each pairing earns its keep.
Alternatives to PathAI
View allFrequently Asked Questions
Categories
Topics
Used PathAI? Help shape our editorial sentiment research.